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Background: Chemokines and their receptors are known to play important roles in the tumorigenesis of many
malignancies. The aim of this study was to evaluate the prognostic impact of the expression of the chemokine
SDF-1 and its receptors CXCR4 and CXCR7 in patients with renal cell carcinoma.
Methods: The expression of CXCR4, CXCR7 and SDF-1 in specimens from 97 renal cell carcinoma patients was
evaluated by immunohistochemistry on a tissue microarray. These results were correlated with the
clinicopathological parameters and survival of the patients.
Results: CXCR4 and CXCR7 were expressed in all patients, whereas SDF-1 was expressed in 61 patients (62.9%). No
association was observed between the expression of CXCR4, CXCR7 or SDF-1 and the clinical or pathological data
except between SDF-1 expression and Fuhrman’s grade (P = 0.015). Patients with high expression of CXCR4, CXCR7
and SDF-1 had shorter overall survival and recurrence-free survival than those with low expression. In a multivariate
analysis, the high expression of CXCR4, CXCR7 and SDF-1 correlated with poor overall survival and recurrence-free
survival independent of gender, age, AJCC stage, lymph node status, metastasis, histologic variant and Fuhrman’s
grade.
Conclusions: High levels of CXCR4, CXCR7 and SDF-1 were associated with poor overall survival and
recurrence-free survival in renal cell carcinoma patients. CXCR4, CXCR7 and SDF-1 may serve as useful prognostic
markers and therapeutic targets for renal cell carcinoma.
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Renal cell carcinoma (RCC) accounts for 2 to 3% of all
malignancies, with a peak incidence in the 5th and 6th
decades of life. Approximately one-third of patients with
RCC have tumor metastasis at the time of diagnosis, and
as many as 40% of them eventually develop distant metas-
tasis [1]. Systemic therapies for metastatic RCC are largely
ineffective in terms of disease response or patient survival,
and the prognosis is usually poor, with a median survival
of less than 1 year [2]. Therefore, defining factors that
may be involved in disease progression and metastasis
would help identify strategies to develop potential targets
for the effective treatment of RCC.* Correspondence: syhchanghai@126.com
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reproduction in any medium, provided the orExtensive studies have suggested that chemokines and
their receptors play a crucial role in tumor growth, angio-
genesis and metastasis [3,4]. Chemokines, cytokines with
molecular masses of 8–10 kDa, are classified into four
groups (CXC, CC, C and CX3C) based on the position of
the first two cysteines [5]. Chemokine stromal-derived fac-
tor 1 (SDF-1), also known as CXCL12, is expressed by
stromal cells such as fibroblasts and endothelial cells [3].
SDF-1 has been shown to regulate many essential bio-
logical processes, including cardiac and neuronal develop-
ment, stem cell motility, angiogenesis, apoptosis and
tumorigenesis. Chemokine receptors belong to the G
protein-coupled receptor (GPCR) superfamily [6]. Among
these receptors, CXCR4, the predominant SDF-1 receptor,
is of particular importance in tumor biology, especially in
tumor metastasis. SDF-1 is generally believed to mediate
many disparate physiological and pathological processes
via CXCR4. Currently, increasing evidence has suggestedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tumor invasion and metastasis [7,8].
Recently, SDF-1 was shown to bind to the orphan re-
ceptor CXCR7, which also binds to the CXCL11 chemo-
kine [9]. CXCR7 is present on the surface of many
different malignant cell types [9] and tumor-associated
blood vessels but not on normal vasculature [10]. Recent
data suggest that CXCR7 has key functions in promoting
tumor development and progression [11,12]. However,
the mechanism underlying the functions of CXCR7 and
its interaction with CXCR4 and SDF-1 remains unclear.
The expression and prognostic impact of CXCR4 in
RCC have been investigated in only a few studies [13],
and even fewer data are available about the expression
of CXCR7 and SDF-1 in RCC. In this study, we evalu-
ated the expression of CXCR4, CXCR7 and SDF-1 and
their relative impact on the outcomes of RCC patients.
Methods
Patients and tissues
Patients with RCC who underwent surgery at Changhai
Hospital, Shanghai, China, from March 2002 to April
2003 were retrospectively reviewed. Formalin-fixed paraf-
fin-embedded (FFPE) archival tissue samples from 97
patients were retrieved from the Department of Pathology.
Our study group consisted of 60 male patients and 37
female patients with a median age of 55.4 years (range,
21–81 years) at the time of surgery. This study was
approved by the Institution Review Board, Changhai Hos-
pital, Second Military Medical University, Shanghai, China.
Tissue microarray (TMA) construction
Tissue cores were obtained from FFPE tissue blocks
from patients with pathologically proven RCC. Repre-
sentative areas of the tumor were selected based on
hematoxylin-eosin staining. For each specimen, two cores
of each carcinoma tissue and its surrounding tissue were
sampled from representative areas using a 1.0-mm punch.
A total of 388 cores with a 1.5-mm diameter were placed
into a recipient block using a precision arraying instru-
ment (Beecher Instruments; Micro Tissue Arrayer, Silver
Springs, MD, USA). Four-micrometer sections were cut
from completed array blocks and transferred to adhesive
slides. The slides were protected against antigen deterior-
ation by paraffin coating before use. The sections were
stained with hematoxylin and assessed for adequate tumor
representation.
Immunohistochemistry
The sections were immunostained using a biotin-streptavidin-
peroxidase method [14]. The sections underwent routine
deparaffinization and rehydration and were then immersed in
10 mM sodium citrate buffer (pH 6.0), boiled for 10 min on a
hot plate and allowed to cool for 20 min. The sectionswere incubated for 10 min in 3% hydrogen peroxide in
distilled water, washed in phosphate-buffered saline (PBS)
three times for 5 min and incubated with 10% normal goat
serum in PBS for 30 min. After three washes in PBS buf-
fer, the sections were incubated overnight at 4°C with
2 μg/ml primary anti-CXCR4 (MAB172, clone 44716,
R&D Systems, Minneapolis, MN, USA), anti-CXCR7
(MAB4227, clone 358426, R&D Systems, Minneapolis,
MN, USA) and anti-CXCL12/SDF-1 (MAB350, clone
79018, R&D Systems, Minneapolis, MN, USA) anti-
bodies. The sections were then incubated with the ap-
propriate biotin-labeled secondary antibodies and
streptavidin-peroxidase (1:30) for 20 min each. The slides
were stained for 5 min with 0.05% 3,30-diaminobenzidine
tetrahydrochloride freshly prepared in 0.05 M Tris–HCl
buffer (pH 7.6) containing 0.024% hydrogen peroxidase
and then counterstained with hematoxylin, dehydrated
and mounted in Diatex.
The staining results were evaluated blindly and inde-
pendently by two pathologists (LG and YW) to deter-
mine the average percentage of positive tumor cells.
Discordant cases were discussed until consensus was
reached. Using the 25th percentile value of the average
percentage of positive tumor cells as a cutoff, we cate-
gorized CXCR4, CXCR7 and SDF-1 expression into
high-expression (CXCR4-H, CXCR7-H, SDF-1-H; cell
staining of ≥ 30% of the tumor cells) and low-expression
(CXCR4-L, CXCR7-L, SDF-1-L; cell staining of < 30% of
the tumor cells or no staining) groups.
Statistical analysis
The chi-squared and Fisher’s exact tests were used to com-
pare the categorical data. Overall survival (OS) and
recurrence-free survival (RFS) curves were constructed
using the Kaplan-Meier method, and the log-rank test was
used to evaluate the statistical significance of the differ-
ences. OS was calculated as the time from the date of diag-
nosis to the date of death or the date of the last follow-up
(if death did not occur). RFS was calculated as the time
from the date of surgery to the date of the first recurrence
after surgery (in patients with recurrence) or the date of
last follow-up (in patients without recurrence). The prog-
nostic significance of the clinical and pathological charac-
teristics was determined by univariate Cox regression
analysis. The Cox proportional hazards models were fitted
for multivariate analysis. The Statistical Package for Social
Sciences 17.0 software (SPSS Inc., Chicago, IL, USA) was
used for the statistical analyses. P values <0.05 were con-
sidered statistically significant.
Results
Characteristics of patients and tumors
Our case series comprised 97 patients with RCC. The
characteristics of the patients and tumors are listed in
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and CXCR7 expression and any clinical or pathological
data. SDF-1 expression revealed an association with
Fuhrman’s grade (P = 0.015). No association with other
data, such as gender, age, AJCC stage, lymph node sta-
tus, metastasis and histologic variant, was observed for
SDF-1 expression.
Expression patterns of CXCR4, CXCR7 and SDF-1 in RCC
CXCR4 and CXCR7 were expressed in all patients, whereas
SDF-1 was expressed only in 61 patients (61/97, 62.9%).
CXCR4 showed a predominantly nucleolar distribution inTable 1 Characteristics of patients and tumors according to C
Characteristics N (%) CXCR4 P
Low High
Gender
Male 60 (61.9) 22 38
Female 37 (38.1) 15 22 0.703
Age (years)
≤60 62 (63.9) 23 39
>60 35 (36.1) 14 21 0.777
Tumor size (cm)
≤4 20 ( 20.6 ) 7 13
4-7 50 (51.5) 20 30
>7 27(27.9) 10 17 0.918
Symptoms at diagnosis
Incidental 56 (57.7) 17 39
Symptoms 41 (42.3) 20 21 0.065
AJCC stage
T1 66 (68.0) 25 41
T2 18 (18.6) 5 13
T3 and T4 13 (13.4) 7 6 0.369
Lymph nodal status
N0 20 (20.6) 11 9
N1 5 (5.2) 1 4
NX 72 (74.2) 25 47 0.22
Metastasis
M0 91 (93.8) 35 56
M1 6 (6.2) 2 4 1
Histologic variant
Clear cell 81 (83.5) 33 48
Others 16 (16.5) 4 12 0.236
Fuhrman’s grade
1 17 (17.5) 8 9
2 50 (51.5) 19 31
3 24 (24.7) 9 15
4 6 (6.3) 1 5 0.676the cancer cells (48/97, 49.5%), with a cytoplasmic distribu-
tion in 24 cases (24/97, 24.7%) and a membrane distribu-
tion in 25 (25/97, 25.8%). CXCR7 staining was mainly
observed in the cytoplasm (84/97, 86.6%), with a mem-
brane distribution in 8 cases (8/97, 8.2%) and a nucleolar
distribution in 5 (5/97, 5.2%). Among the 61 cases expres-
sing SDF-1, the majority of SDF-1 expression was localized
on the cell membrane (51/97, 52.6%), with a cytoplasmic
distribution in 8 cases (8/97, 8.2%) and a nucleolar distribu-
tion in 2 (2/97, 2.1%). In this study, 60 out of 97 patients
(61.9%) expressed CXCR4 at a high level (Figure 1A) and
37/97 (38.1%) at a low level (Figure 1B). In addition,XCR4, CXCR7 and SDF-1 expression
CXCR7 P SDF-1 P
Low High Low High
17 43 41 19
8 29 0.463 29 8 0.284
18 44 44 18
7 28 0.329 26 9 0.726
7 13 12 8
14 36 37 13
4 23 0.257 21 6 0.371
15 41 43 13
10 31 0.79 27 14 0.235
18 48 44 22
5 13 15 3
2 11 0.774 11 2 0.289
6 14 15 5
1 4 2 3
19 53 0.914 53 19 0.264
22 69 66 25
3 3 0.176 4 2 0.669
21 60 60 21
4 12 1 10 6 0.369
7 10 7 10
13 37 41 9
5 19 18 6
0 6 0.235 4 2 0.015
Figure 1 CXCR4, CXCR7 and SDF-1 expression in RCC. The following representative examples are shown: (A) high and (B) low expression of
CXCR4; (C) high and (D) low expression of CXCR7; and (E) high, (F) low and (G) negative expression of SDF-1 (magnification 200×, inset detail
400×). CXCR4 showed a predominantly nucleolus distribution. CXCR7 staining was mainly observed in the cytoplasm. SDF-1 was mainly localized
on the cell membrane.
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of 97 (74.2%) and at a low level (Figure 1D) in 25/97
(25.8%), and SDF-1 was expressed at a high level (Figure 1E)
in 27 out of 97 (27.8%) and at a low level (Figure 1F)
in 70/97 (72.2%). The 36 patients who were negative for
the expression of SDF-1 were also grouped as having a
low expression level (Figure 1G).
Comparison of CXCR4, CXCR7 and SDF-1 expression
between carcinoma and the surrounding tissues
The expression of CXCR4, CXCR7 and SDF-1 between
carcinoma tissues (CT) and the surrounding tissues (ST)
was compared. The expression of CXCR4 in the CT was
higher than in the ST (60 specimens with high expres-
sion and 37 with low expression in CT vs. 31 with high
expression and 66 with low expression in ST, P < 0.001).
The expression pattern of CXCR7 was similar (72 with
high expression and 25 with low expression in CT vs. 53
with high expression and 44 with low expression in ST,
P = 0.004). In contrast, the expression of SDF-1 in CT
was lower than in ST (27 with high expression and 70
with low expression in CT vs. 77 with high expression
and 20 with low expression in ST, P < 0.001).
High CXCR4, CXCR7 and SDF-1 expression predicts poor
prognosis of RCC
To evaluate the prognostic impact of CXCR4, CXCR7
and SDF-1, patient outcome was correlated with the ex-
pression of these molecules. The patients with tumorshaving CXCR4-H, CXCR7-H and SDF-1-H expression
had a worse prognosis than those with CXCR4-L,
CXCR7-L and SDF-1-L expression (Figure 2). The me-
dian OS and RFS for patients with CXCR4-H expression
were 88.1 and 80.1 months, respectively, compared with
108.8 and 106.5 months for patients with CXCR4-L ex-
pression (P = 0.010 and P = 0.004, Figure 2A, 2D).
Patients with CXCR7-L expression showed a median OS
of 107.9 months, which was significantly longer than
that of patients with CXCR7-H expression (91.8 months;
P = 0.033, Figure 2B). The RFS in patients with CXCR7-
L and CXCR7-H expression followed a similar pattern,
with patients with CXCR7-L expression showing a
longer RFS (103.4 months) compared with those with
CXCR7-H expression (85.5 months, P = 0.040, Figure 2E).
Patients with SDF-1-L expression had a better prognosis
than those with SDF-1-H expression in terms of OS
(101.7 months versus 81.2 months, P = 0.042, Figure 2C)
and RFS (97.4 months versus 71.8 months, P = 0.033,
Figure 2F).
The analysis of prognostic factors for OS and RFS is
summarized in Table 2. Metastasis and the expression
levels of CXCR4, CXCR7 and SDF-1 had significant
prognostic values in the univariate analysis. In the multi-
variate analysis, high CXCR4, CXCR7 and SDF-1 expres-
sion was significantly correlated with poor OS and RFS
in patients with RCC independent of gender, age, AJCC
stage, lymph node status, metastasis, histologic variant
and Fuhrman’s grade.
Figure 2 Kaplan-Meier curves for overall survival and recurrence-free survival according to the expression levels of CXCR4, CXCR7 and
SDF-1 in an RCC patient. Patients with high expression of CXCR4, CXCR7 and SDF-1 had shorter overall survival (A, B, C) and recurrence-free
survival (D, E, F) than those with low expression.
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In this study, we examined the expression of CXCR4,
CXCR7 and SDF-1 in 97 RCCs by immunohistochemis-
try and evaluated their impact on patient outcome. We
found that a high level of CXCR4, CXCR7 and SDF-1
expression was significantly associated with poor OS and
RFS. These molecules could be regarded as prognostic
factors for patients with RCC independent of gender,
age, AJCC stage, lymph node status, metastasis, histo-
logic variant and Fuhrman’s grade.
The expression pattern of CXCR4 in 48 (49.5%) RCC
specimens showed predominantly nucleolar staining,
with only 24 (24.7%) showing predominantly cytoplas-
mic staining and 25 (25.8%) showing predominantly
membranous staining. These results were different from
those in some previously published studies. Zagzag et al.
[13] reported that cytoplasmic staining of CXCR4 was
observed in all specimens of RCC, with fewer cases show-
ing additional membranous or nucleolar localization. Nu-
clear CXCR4 expression has been described in breast
cancer [15] and lung cancer [16], which suggests that nu-
clear CXCR4 staining predicts lymphatic invasion and
lymph node metastasis of cancer. In our study, only five
patients were observed with lymph node metastasis and
six with distant metastasis, which is not enough to evalu-
ate the relationship between CXCR4 nuclear localization
and clinical data. However, in our previous study, wefound that CXCR4 nuclear localization may be responsible
for certain metastatic changes in cancer cells [17]. Due to
the limitation of a small number of samples, identifying
the mechanism involved in the differential localization of
CXCR4 in a further study is necessary. D’Alterio et al. [18]
investigated the expression of CXCR7 in RCC and found
that CXCR7 staining was localized to the cytoplasm and/
or on the cell membrane, with prevalent membranous
staining. Nevertheless, in our study, CXCR7 staining was
mainly localized to the cytoplasm, with less nucleolar and
membranous localization. SDF-1 staining was prevalently
localized to the cell membrane, which was different from
the discovery by Zagzag et al. [13], who found SDF-1
staining was mainly localized to the nucleus. Similarly, the
mechanism behind the differential localization of CXCR7
and SDF-1 also needs to be investigated in a future study.
There is growing evidence that the SDF-1/CXCR4 axis is
important for tumor proliferation, survival, vascularization
and metastasis [3]. Tumor cells have been shown to trans-
fer from their primary site to a metastatic site under a
concentration gradient of SDF-1. We compared the ex-
pression of SDF-1 between carcinoma tissue and the
surrounding normal tissue by immunohistochemistry.
The result revealed a low expression of SDF-1 within
the carcinoma tissue compared with the surrounding
tissue. There was high expression of SDF-1 in tissues
such as the lymph nodes, lungs, liver and bones, which
Table 2 Univariate and multivariate analysis of overall survival and recurrence-free survival in patients with renal cell
carcinoma
Covariate Univariate analysis Multivariate analysis
OS RFS OS RFS
HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P
Gender (male vs. female) 0.941 0.862 0.939 0.844 0.887 0.75 0.876 0.705
(0.474, 1.869) (0.504, 1.752) (0.422, 1.861) (0.443, 1.734)
Age (≤60 vs. >60 years) 1.459 0.269 1.043 0.897 1.759 0.141 1.112 0.769
(0.747, 2.850) (0.554, 1.961) (0.829, 3.734) (0.549, 2.251)
Tumor size (≤4 vs. 4–7 vs. >7cm) 1.399 0.145 1.448 0.083 1 0.999 0.898 0.715
(0.890, 2.198) (0.953, 2.199) (0.539, 1.854) (0.503, 1.602)
Symptoms at diagnosis 1.951 0.05 1.605 0.126 2.35 0.04 1.745 0.121
(incidental vs. symptoms) (1.001, 3.800) (0.875, 2.942) (1.038, 5.318) (0.863, 3.527)
AJCC stage (T1 vs. T2 vs. T3-T4) 1.325 0.153 1.351 0.104 0.96 0.881 1.123 0.643
(0.901, 1.950) (0.940, 1.942) (0.565, 1.633) (0.688, 1.831)
Lymph nodal status 1.079 0.725 1.097 0.637 0.997 0.989 0.962 0.861
(N0 vs. N1 vs. Nx) (0.706, 1.649) (0.746, 1.613) (0.613, 1.620) (0.620, 1.490)
Metastasis (M0 vs. M1) 3.389 0.023 4.324 0.003 5.109 0.014 6.807 0.001
(1.187, 9.677) (1.642, 11.391) (1.390, 18.787) (2.103, 22.035)
Histologic variant 1.587 0.339 1.565 0.31 1.486 0.521 2.167 0.157
(clear cell vs. others) (0.615, 4.091) (0.659, 3.715) (0.443, 4.981) (0.734, 6.319)
Fuhrman’s grade 1.363 0.173 1.268 0.26 1.316 0.274 1.105 0.675
(1 vs. 2 vs. 3 vs. 4) (0.873, 2.130) (0.839, 1.918) (0.805, 2.151) (0.693, 1.761)
CXCR4 (low vs. high) 3.994 0.002 3.772 0.001 6.946 <0.001 8.034 <0.001
(1.655, 9.639) (1.741, 8.169) (2.498, 19.314) (3.192, 20.221)
CXCR7 (low vs. high) 4.465 0.013 3.195 0.015 5.506 0.01 6.059 0.001
(1.366, 14.594) (1.254, 8.139) (1.506, 20.129) (2.013, 18.237)
SDF-1 (low vs. high) 3.344 <0.001 3.206 <0.001 11.406 <0.001 14.025 <0.001
(1.713, 6.527) (1.734, 5.928) (4.718, 27.576) (5.864,33.542)
OS, overall survival; RFS, recurrence-free survival; HR, hazard rate; CI, confidence interval.
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our study, the fact that the expression of SDF-1 in the
surrounding tissue was higher than that of carcinoma
tissue predicted a higher propensity to metastasis from
the primary tumor site. Thus, a possible channel was
constructed from the carcinoma and surrounding nor-
mal tissue to a metastatic site following a SDF-1 con-
centration gradient that facilitates the metastasis of
cancer cells. In contrast with our results, Zagzag et al.
[13] revealed the overexpression of SDF-1 within RCC
tumor cells. The expression of CXCR4 and CXCR7 was
increased in areas of malignancy compared with the nor-
mal cells, consistent with some previous studies [18].
An interesting phenomenon in our study was that all
the specimens expressed both CXCR4 and CXCR7,
which underlines the functional affiliation between the
two molecules. The role of CXCR7 has been identified
by studies in malignant cells of various tumor types, includ-
ing breast, lung, prostate and colorectal cancer, highlightingthe role of CXCR7 in cancer growth, survival, adhesion, in-
vasion and metastasis [19]. Miao et al. [10] showed that
CXCR7 promotes the tumor growth of breast and lung
cancer cells and lung metastases in both immunodeficient
and immunocompetent mouse models. Wang et al. [12]
reported that CXCR7 was associated with a survival advan-
tage for tumors by enhancing the adhesive and invasive
properties of prostate cancer cells in vitro and in vivo. Un-
like many other chemokine receptors, such as CXCR4,
CXCR7 does not cause calcium mobilization or cell chemo-
taxis [20]. Growing evidence has suggested that CXCR7
functions as a decoy receptor that does not activate the Gi
pathways of a chemokine receptor, which would result in
GTP hydrolysis or calcium mobilization [9]. CXCR7 was
proposed to potentially serve as a co-receptor for CXCR4
and enhance SDF-1-mediated G-protein signaling [21] be-
cause the two receptors form heterodimers when they are
overexpressed in transiently transfected cells. These results
suggest that ligand binding to CXCR7 results in crosstalk
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Although CXCR7 has been identified to be important in
cancer progression and metastasis, its mechanism of action
is not completely understood. Thus, further studies should
focus on the functions and interactions between CXCR7,
its ligand SDF-1 and the other members of the chemokine
family.
Several studies have identified the relationships among
CXCR4, CXCR7 and SDF-1 and the clinical and histo-
pathological parameters of various cancer types as well
as patient prognosis. In a cohort of 72 stage II pancreatic
ductal adenocarcinoma patients, Liang et al. [22] showed
that there was no significant association between SDF-1
and any of the clinical and histopathological parameters.
They also found that high SDF-1 expression correlated
with poor OS and RFS independent of tumor size, differ-
entiation and lymph node status. D’Alterio et al. [18]
reported that high expression levels of CXCR4 and
CXCR7 predicted shorter RFS and that these molecules
were valuable prognostic factors in RCC patients. In
contrast with previous studies, Gebauer et al. [23] showed
that OS and RFS revealed no association with either
CXCR4 or CXCR7 expression in pancreatic adenocarcin-
oma. In our study, we found there were no associations
between the expression of CXCR4, CXCR7 or SDF-1 and
the clinical or pathological data, except between SDF-1
expression and Fuhrman’s grade. The patients with high
expression levels of CXCR4, CXCR7 or SDF-1 had shorter
OS and RFS than the patients with low expression levels
of these three molecules, which was partly in agreement
with the results of D’Alterio et al. [18]. There is no report
on the relationship of SDF-1 expression with OS or RFS
in RCC patients. Univariate and multivariate analyses
revealed that high expression levels of CXCR4, CXCR7
and SDF-1 are independent prognostic factors for RCC
patients, which suggested that new potential therapeutic
strategies targeted at these molecules would improve the
prognosis of RCC patients.
There is evidence that blocking CXCR4 can inhibit the
proliferation, invasion and metastasis of tumor cells
[24,25]. Some small molecule CXCR4 antagonists, such
as Plerixafor (AMD3100) and T140 analogs (TN14003/
BKT140), are currently being tested in clinical trials [26].
The involvement of CXCR7 in the expansion and metas-
tasis of several tumor types shows that blocking CXCR7
could also be employed as a therapeutic strategy. Some
small molecular CXCR7 inhibitors, such as CCX733 or
CCX266, siRNA and blocking antibodies, are already
employed in experimental models in vitro and in vivo
[27]. Burns et al. [9] showed that high affinity CCX754, a
small molecule antagonist of CXCR7, impeded in vivo
tumor growth in animal models. These results indicate
that therapeutic strategies targeted at CXCR4 or CXCR7
have a bright future in cancer treatment.Conclusions
In summary, our study shows that the expression of
CXCR4, CXCR7 and SDF-1 in RCC predicts poor OS
and RFS of patients. Because these molecules are not
associated with other clinicopathological factors, they
may be ideal molecular markers to identify patients who
are at higher risk for recurrence after surgery. Small
molecule CXCR4, CXCR4 and SDF-1 antagonists could
be attractive therapeutic candidates in future clinical
trials for renal cancer. Additionally, further studies are
needed to define the interactions among CXCR4,
CXCR7 and SDF-1.
Abbreviations
RCC: Renal cell carcinoma; SDF-1: Stromal-derived factor 1; GPCR: G protein-
coupled receptor; TMA: Tissue microarray; FFPE: Formalin-fixed paraffin-
embedded; PBS: Phosphate-buffered saline; OS: Overall survival;
RFS: Recurrence-free survival.
Competing interests
The authors declare that they have no competing interest.
Authors’ contributions
LHW participated in the design of the study and performed the statistical
analysis. WC carried out the data collection and drafted the manuscript. LG
participated in the construction of the tissue microarray and immunoassays.
QY and BL carried out the follow-up. ZJW participated in the analysis of
experimental results. YW carried out the immunoassays. YHS conceived of
the study, participated in its design and coordination, and helped to draft
the manuscript. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by the Science and Technology key project of
basic research of Shanghai, China (no. 10JC1417800).
Author details
1The Department of Urology, Changhai Hospital, Second Military Medical
University, Shanghai, China. 2The Department of Pathology, Changhai
Hospital, Second Military Medical University, Shanghai, China.
Received: 17 August 2012 Accepted: 26 September 2012
Published: 7 October 2012
References
1. Jones J, Libermann TA: Genomics of renal cell cancer: the biology behind
and the therapy ahead. Clin Cancer Res 2007, 13:685s–692s.
2. Pantuck AJ, Zisman A, Dorey F, Chao DH, Han KR, Said J, Gitlitz B,
Belldegrun AS, Figlin RA: Renal cell carcinoma with retroperitoneal lymph
nodes. Impact on survival and benefits of immunotherapy. Cancer 2003,
97:2995–3002.
3. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T,
Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A:
Involvement of chemokine receptors in breast cancer metastasis. Nature
2001, 410:50–56.
4. Lazennec G, Richmond A: Chemokines and chemokine receptors: new
insights into cancer-related inflammation. Trends Mol Med 2010,
16:133–144.
5. Zlotnik A, Yoshie O: Chemokines: a new classification system and their
role in immunity. Immunity 2000, 12:121–127.
6. Murphy PM, Baggiolini M, Charo IF, Hébert CA, Horuk R, Matsushima K,
Miller LH, Oppenheim JJ, Power CA: International union of
pharmacology. XXII. Nomenclature for chemokine receptors.
Pharmacol Rev 2000, 52:145–176.
7. Schimanski CC, Galle PR, Moehler M: Chemokine receptor CXCR4-
prognostic factor for gastrointestinal tumors. World J Gastroenterol 2008,
14:4721–4724.
8. Matsusue R, Kubo H, Hisamori S, Okoshi K, Takagi H, Hida K, Nakano K, Itami
A, Kawada K, Nagayama S, Sakai Y: Hepatic stellate cells promote liver
Wang et al. World Journal of Surgical Oncology 2012, 10:212 Page 8 of 8
http://www.wjso.com/content/10/1/212metastasis of colon cancer cells by the action of SDF-1/CXCR4 axis. Ann
Surg Oncol 2009, 16:2645–2653.
9. Burns JM, Summers BC, Wang Y, Melikian A, Berahovich R, Miao Z, Penfold
ME, Sunshine MJ, Littman DR, Kuo CJ, Wei K, McMaster BE, Wright K,
Howard MC, Schall TJ: A novel chemokine receptor for SDF-1 and I-TAC
involved in cell survival, cell adhesion, and tumor development. J Exp
Med 2006, 203:2201–2213.
10. Miao Z, Luker KE, Summers BC, Berahovich R, Bhojani MS, Rehemtulla A,
Kleer CG, Essner JJ, Nasevicius A, Luker GD, Howard MC, Schall TJ: CXCR7
(RDC1) promotes breast and lung tumor growth in vivo and is expressed
on tumor-associated vasculature. Proc Natl Acad Sci U S A 2007,
104:15735–15740.
11. Hattermann K, Held-Feindt J, Lucius R, Müerköster SS, Penfold ME, Schall TJ,
Mentlein R: The chemokine receptor CXCR7 is highly expressed in
human glioma cells and mediates antiapoptotic effects. Cancer Res 2010,
70:3299–3308.
12. Wang J, Shiozawa Y, Wang J, Wang Y, Jung Y, Pienta KJ, Mehra R, Loberg R,
Taichman RS: The role of CXCR7/RDC1 as a chemokine receptor for
CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008, 283:4283–4294.
13. Zagzag D, Krishnamachary B, Yee H, Okuyama H, Chiriboga L, Ali MA,
Melamed J, Semenza GL: Stromal cell-derived factor-1alpha and CXCR4
expression in hemangioblastoma and clear cell-renal cell carcinoma: von
Hippel-Lindau loss-of-function induces expression of a ligand and its
receptor. Cancer Res 2005, 65:6178–6188.
14. Li Q, Bavikatty N, Michael CW: The role of immunohistochemistry in
distinguishing squamous cell carcinoma from mesothelioma and
adenocarcinoma in pleural effusion. Semin Diagn Pathol 2006, 23:15–19.
15. Woo SU, Bae JW, Kim CH, Lee JB, Koo BW: A significant correlation
between nuclear CXCR4 expression and axillary lymph node metastasis
in hormonal receptor negative breast cancer. Ann Surg Oncol 2008,
15:281–285.
16. Na IK, Scheibenbogen C, Adam C, Stroux A, Ghadjar P, Thiel E, Keilholz U,
Coupland SE: Nuclear expression of CXCR4 in tumor cells of non-small
cell lung cancer is correlated with lymph node metastasis. Hum Pathol
2008, 39:1751–1755.
17. Wang L, Wang Z, Yang B, Yang Q, Wang L, Sun Y: CXCR4 nuclear
localization follows binding of its ligand SDF-1 and occurs in metastatic
but not primary renal cell carcinoma. Oncol Rep 2009, 22:1333–1339.
18. D’Alterio C, Consales C, Polimeno M, Franco R, Cindolo L, Portella L, Cioffi M,
Calemma R, Marra L, Claudio L, Perdonà S, Pignata S, Facchini G, Cartenì G,
Longo N, Pucci L, Ottaiano A, Costantini S, Castello G, Scala S: Concomitant
CXCR4 and CXCR7 expression predicts poor prognosis in renal cancer.
Curr Cancer Drug Targets 2010, 10:772–781.
19. Hou KL, Hao MG, Bo JJ, Wang JH: CXCR7 in tumorigenesis and
progression. Chin J Cancer 2010, 29:456–459.
20. Thelen M, Thelen S: CXCR7, CXCR4 and CXCL12: an eccentric trio? J
Neuroimmunol 2008, 198:9–13.
21. Levoye A, Balabanian K, Baleux F, Bachelerie F, Lagane B: CXCR7
heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein
signaling. Blood 2009, 113:6085–6093.
22. Liang JJ, Zhu S, Bruggeman R, Zaino RJ, Evans DB, Fleming JB, Gomez HF,
Zander DS, Wang H: High levels of expression of human stromal cell-
derived factor-1 are associated with worse prognosis in patients with
stage II pancreatic ductal adenocarcinoma. Cancer Epidemiol Biomarkers
Prev 2010, 19:2598–2604.
23. Gebauer F, Tachezy M, Effenberger K, von Loga K, Zander H, Marx A, Kaifi JT,
Sauter G, Izbicki JR, Bockhorn M: Prognostic impact of CXCR4 and CXCR7
expression in pancreatic adenocarcinoma. J Surg Oncol 2011, 104:140–145.
24. Rubin JB, Kung AL, Klein RS, Chan JA, Sun Y, Schmidt K, Kieran MW, Luster
AD, Segal RA: A small-molecule antagonist of CXCR4 inhibits intracranial
growth of primary brain tumors. Proc Natl Acad Sci U S A 2003,
100:13513–13518.25. Smith MC, Luker KE, Garbow JR, Prior JL, Jackson E, Piwnica-Worms D, Luker
GD: CXCR4 regulates growth of both primary and metastatic breast
cancer. Cancer Res 2004, 64:8604–8612.
26. Burger JA, Stewart DJ: CXCR4 chemokine receptor antagonists:
perspectives in SCLC. Expert Opin Investig Drugs 2009, 18:481–490.
27. Hartmann TN, Grabovsky V, Pasvolsky R, Shulman Z, Buss EC, Spiegel A,
Nagler A, Lapidot T, Thelen M, Alon R: A crosstalk between intracellular
CXCR7 and CXCR4 involved in rapid CXCL12-triggered integrin activation
but not in chemokine-triggered motility of human T lymphocytes and
CD34+ cells. J Leukoc Biol 2008, 84:1130–1140.
doi:10.1186/1477-7819-10-212
Cite this article as: Wang et al.: High expression of CXCR4, CXCR7 and
SDF-1 predicts poor survival in renal cell carcinoma. World Journal of
Surgical Oncology 2012 10:212.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
